Selective MC2R Antagonists for ACTH-Driven Cortisol Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions like Cushing's syndrome, Cushing's disease, ectopic ACTH syndrome, congenital adrenal hyperplasia, depressive illness, and septic shock often have unwanted side effects due to the non-specific modulation of melanocortin receptors, particularly MC2R, which are activated by ACTH.
Innovation Solution
Development of selective MC2R antagonists that modulate the activity of the melanocortin subtype-2 receptor (MC2R) to treat these conditions without affecting other melanocortin receptors, thereby reducing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If non-specific modulation of melanocortin receptors is used to treat conditions like Cushing's syndrome, then treatment coverage is broad, but side effects increase due to lack of selectivity
Solution Approach 1:
The patent segments the melanocortin receptor family into individual targets, specifically focusing on MC2R as a distinct therapeutic target. By designing compounds that selectively modulate MC2R rather than all melanocortin receptors, the treatment achieves specificity while maintaining effectiveness for ACTH-dependent conditions.
Solution Approach 2:
The invention applies local quality by creating compounds with specific molecular characteristics that confer selectivity for MC2R. The chemical structures described (Formula I and Formula II compounds) possess specific functional groups and spatial arrangements that enable preferential binding to MC2R over other melanocortin receptors, thereby reducing off-target effects.
2Reliability
If selective MC2R antagonists are developed to reduce side effects, then treatment specificity improves, but development complexity increases
Solution Approach 1:
The patent employs parameter changes by systematically modifying chemical parameters of the compounds to optimize MC2R selectivity. The invention describes specific ranges for substituents (R1-R6, Ra-Rf), molecular weight, and structural features that enhance binding affinity for MC2R while maintaining drug-like properties, thereby managing development complexity through defined chemical space.
Solution Approach 2:
The invention uses computational chemistry and in silico methods as intermediaries to predict and optimize compound selectivity before synthesis. Molecular modeling and docking studies serve as intermediary tools to guide the design of selective MC2R antagonists, reducing the need for extensive trial-and-error experimentation.
Data Source
AI summary
Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of MC2R activity.